Laddar…
Academic Journal
Effect of Tricin on cardiomyocyte damage caused by diabetic cardiomyopathy (DCM)
Rong Yu, Yaping Zhang, Tong Wang, Jinju Duan, Xiaoming Li
BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-8 (2024)
Sparad:
Titel | Effect of Tricin on cardiomyocyte damage caused by diabetic cardiomyopathy (DCM) |
---|---|
Författarna | Rong Yu, Yaping Zhang, Tong Wang, Jinju Duan, Xiaoming Li |
Utgivningsår |
2024
|
Källa |
BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-8 (2024)
|
Beskrivning |
Abstract Objectives Flavonoid compounds exhibit remarkable antioxidant and anti-inflammatory properties in DCM and various other diseases. However, the specific mechanisms by which Tricin, 4’,5,7-trihydroxy-3‘,5’-dimethoxyflavone, exerts its effects in the context of DCM remain to be elucidated. Methods Rat H9C2 cells were cultured and subjected to high glucose conditions to establish a DCM cell model. Tricin was administered in varying concentrations to evaluate its effects on cellular oxidative stress markers, including ROS, LDH, and SOD. Additionally, the levels of inflammatory cytokines TNF-α, IL-1β, and IL-6, as well as the expression of TLR4, MYD88, and p-NF-κB, were assessed through ELISA and Western blotting. Results Tricin treatment significantly ameliorated high glucose-induced oxidative stress in H9C2 cells, evidenced by reduced ROS and LDH levels and increased SOD levels in a dose-dependent manner. Furthermore, Tricin effectively suppressed the elevation of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. Tricin also inhibited the overactivation of the TLR4-MYD88-NF-κB signaling pathway, suggesting its role in modulating key inflammatory processes in DCM. Conclusions Tricin exhibits a protective role against high glucose-induced cardiac damage in a DCM cell model. By reducing oxidative stress and inflammation, and inhibiting the TLR4-MYD88-NF-κB pathway, Tricin shows significant therapeutic potential for DCM treatment. This study underscores the value of Tricin as a novel therapeutic approach for managing diabetic cardiomyopathy, warranting further research and clinical investigation. Clinical trial number Not applicable.
|
Dokumenttyp |
article
|
Språk |
English
|
Information om utgivare |
BMC, 2024.
|
Ämnestermer | |